May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Concentration of Cytokines After Intravitreous Injection of Bevacizumab or Triamcinolone
Author Affiliations & Notes
  • H. Otsuka
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • N. Arimura
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • Y. Kii
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • K. Yamakiri
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • N. Doi
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • T. Hashiguchi
    Kagoshima University, Kagoshima, Japan
    Laboratory Medicine,
  • I. Maruyama
    Kagoshima University, Kagoshima, Japan
    Laboratory Medicine,
  • T. Sakamoto
    Kagoshima University, Kagoshima, Japan
    Ophthalmology,
  • Footnotes
    Commercial Relationships  H. Otsuka, None; N. Arimura, None; Y. Kii, None; K. Yamakiri, None; N. Doi, None; T. Hashiguchi, None; I. Maruyama, None; T. Sakamoto, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5592. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Otsuka, N. Arimura, Y. Kii, K. Yamakiri, N. Doi, T. Hashiguchi, I. Maruyama, T. Sakamoto; Concentration of Cytokines After Intravitreous Injection of Bevacizumab or Triamcinolone. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5592.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the vitreous cytokine levels after intravitreous injection of bevacizumab (Bzab) or triamcinolone (TA) for proliferative diabetic retinopathy (PDR).

Methods: : We investigated 35 eyes of 35 cases with PDR. One week before vitrectomy, 9 eyes were injected with 1.25 mg of Bzab (Avastin, Bzab group) and 8 eyes were injected with 4 mg of TA (TA group). Eighteen eyes without any injection were used for control (control group). Vitreous samples were collected before vitrectomy. The amount of vascular endothelial growth factor (VEGF) levels and stromal cell-derived factor (SDF)-1 levels were measured by enzyme-linked immunosorbent assay(ELIZA). Other cytokines, such as interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12, or TNF-α were quantified by cytometric bead array. We compared 3 groups with statistical analysis (Mann-Whitney test).

Results: : Bzab group had a mean VEGF concentration of 18.5 pg/ml, TA group had that of 1266.8 pg/ml and control group had that of 568.9 pg/ml. VEGF concentration of Bzab group was significantly lower than either of TA group or control group (P<0.01, respectively). Bzab group had a mean SDF-1 concentration of 101.2 pg/ml, TA group had that of 105.3 pg/ml, and control group had that of 282.3 pg/ml. SDF-1 concentration of control group was significantly higher than that of Bzab group or or TA group (P<0.01, respectively). No significant differences were found in any other cytokines between groups.

Conclusions: : Intravitreous injection of Bzab decreased the vitreous concentration of both VEGF and SDF-1. While, intravitreous TA decreased SDF-1 alone. This might have something to do with the dramatic anti-angiogenic effect of Bzab.

Keywords: diabetic retinopathy • cytokines/chemokines • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×